Participated · Series B · Apr 2026

Restore Vision is developing optogenetics-based gene therapies, notably its lead program RV-001 which introduces a proprietary light-sensor protein called Chimera Rhodopsin into retinal interneurons via AAV intravitreal injection. The approach targets retinal diseases such as retinitis pigmentosa where photoreceptors have been lost. The company has completed first patient administration in a Phase I/II clinical trial of RV-001 at Keio University Hospital. Restore Vision plans to advance global clinical development of RV-001 and to pursue research and development of a second pipeline. Financially, the company has raised approximately ¥3.5 billion in equity to date and received about ¥2.1 billion in AMED grants, totaling roughly ¥5.8 billion in funding, with potential for an additional ¥4.5 billion through the AMED project.

Led · Series A · Mar 2026

Kupando develops therapies addressing unmet needs in cancer and infectious diseases by harnessing innate immune stimulation and induction of trained innate immunity via dual Toll‑Like Receptor (TLR) agonists. Its lead candidate, KUP101, is a differentiated dual TLR4 and TLR7 agonist with a preclinical profile and a stated clear path to the clinic. The company plans to use the newly raised Series A funds to advance KUP101’s Phase 1b clinical study in advanced solid tumors and to accelerate its infectious‑disease preclinical programs. Kupando is led by CEO and Founder Johanna Holldack and is based in Schönefeld, Germany. Financially, the latest €10M Series A tranche brought the total capital raised to $23M.

Participated · Series C · Apr 2025

Glycomine is a clinical-stage biotech based in San Carlos, California, focused on developing transformative therapies for rare orphan diseases. Its lead candidate, GLM101, is a first-in-class mannose-1-phosphate replacement therapy designed to deliver mannose-1-phosphate into cells and bypass disease-causing PMM2 mutations to restore N-glycosylation. GLM101 has received Orphan Drug Designation in the U.S. and E.U., and Rare Pediatric Disease and Fast Track designations in the U.S. The company has enrolled more than 20 patients across Europe and the U.S. in an ongoing Phase 2 open-label study and has initiated dosing in pediatric patients. Data from the Phase 2 open-label study showed an average 11.9-point improvement on the ICARS among nine adult and adolescent patients over 24 weeks, providing clinical proof of concept for improvement in ataxia. Glycomine recently announced a $115 million Series C financing to support advancing GLM101 into a randomized, placebo-controlled Phase 2b safety and efficacy study later this year. Glycomine is a biotechnology company based in San Carlos, California, developing therapies for orphan diseases. Its lead candidate, GLM101, is a mannose-1-phosphate substrate replacement therapy designed to deliver mannose-1-phosphate intracellularly to bypass PMM2 enzyme deficiency and restore N-glycosylation. Preclinical studies have shown GLM101 can restore disrupted glycosylation pathways in PMM2-CDG. GLM101 has received Orphan Drug Designation in the U.S. and Europe and Rare Pediatric Disease Designation in the U.S. Glycomine plans to use the Series B proceeds to advance GLM101 into initial clinical trials and confirm clinical potential across PMM2-CDG genotypes. The company focuses on replacement therapies targeted to clinically relevant cellular compartments for rare metabolic and protein-misfolding disorders. Glycomine focuses on developing orphan drugs for serious rare monogenic disorders of metabolism and protein misfolding. The company’s approach combines replacement therapies—substrates, enzymes, or proteins—with delivery vehicles made of bio-nanomaterials or ligands to target molecules to the cell interior of relevant organs. Glycomine intends to use the new capital to advance its substrate replacement therapy for PMM2‑CDG (CDG‑1a) into early-stage clinical studies. The company raised $33m in a Series B financing led by Novo Holdings A/S. In connection with the financing, Peter McWilliams, Ph.D., moved from acting CEO to full-time CEO. Kenneth Harrison, Ph.D., of Novo Ventures and Chris Starr, Ph.D., joined the company’s board. Glycomine is a San Francisco, CA–based biotechnology company developing a new generation of replacement therapies for rare monogenic disorders of metabolism and protein misfolding. Its approach combines replacement therapies—substrates, enzymes, or proteins—with intracellular delivery vehicles consisting of bio‑nanomaterials or targeting ligands to deliver molecules into clinically relevant organs. The company is led by CEO Agnes Rafalko, PhD, with Christopher Starr, PhD serving as Executive Chairman. Glycomine raised $12m in a Series A financing to advance its pipeline. The company intends to use the funds to complete IND‑enabling preclinical studies and initiate clinical studies of a substrate replacement therapy in patients with Congenital Disorder of Glycosylation Type Ia (CDG‑Ia). Proceeds will also be used to accelerate discovery efforts toward an enzyme replacement therapy for N‑glycanase deficiency (Ngly1).

Participated · Series A · Jan 2025

Immunis is a clinical-stage biotechnology company developing stem cell‑derived, multi-active biologics using its multi-active secretome technology to deliver natural human immune modulators. Its lead investigational product, IMM01‑STEM, is being developed to address age-related muscle atrophy and metabolic dysfunction in elderly patients. A Phase 1/2a trial in nine elderly patients showed safety, tolerability and suggestive efficacy, including improvements in quality-of-life measures and gait speed. Preclinical studies in aged mouse models published in GeroScience and Aging Cell showed reversal of muscle atrophy, improved muscle function, enhanced metabolism and reduced body and liver fat. The company describes itself as the leading biotech with the most advanced stem cell‑derived multi-active biologic in human clinical trials. The recently closed financing will fund two Phase 2 clinical trials to further test IMM01‑STEM’s efficacy in targeted elderly populations. Immunis is a private biotech developing a novel immunomodulatory secretome product line (STEM) to address age- and disease-related immune decline. The STEM product line leverages stem cell technology to deliver all-natural, all-human immune modulators in their natural, relative physiological concentrations. Its lead secretome treatment, IMM01-STEM, is described as using natural immunomodulators with potent cytoskeletal remodeling properties. The company plans to use the new funding to support clinical assessment of IMM01-STEM in an FDA-awarded Phase 1/2a clinical trial targeting muscle atrophy. The trial targets muscle atrophy, a condition the article states is experienced by 100% of the population in age, disuse, and disease contexts. Immunis is based in Irvine, California.

Led · Series B · Jan 2024

Cyrano Therapeutics is a clinical-stage regenerative medicine company based in Delray Beach, FL, focused on developing therapies for patients with loss of smell and taste. Its lead program is CYR-064, an intranasal theophylline spray intended to treat post-viral hyposmia. The company is conducting FLAVOR, a Phase 2, randomized, double-blind, placebo-controlled, multi-dose, multi-site trial enrolling 150 subjects at up to 15 U.S. sites. Cyrano intends to use recent financing to advance the FLAVOR trial. The company is led by President and CEO Rick Geoffrion. It is positioned as a clinical-stage developer advancing a first-of-its-kind treatment for long-term smell loss due to viral infection. Cyrano Therapeutics is a clinical-stage regenerative medicine company developing a novel intranasal therapy to restore smell and flavor. Its lead product, CYR-064, is in development to treat chronic smell and flavor loss and the company plans to complete a Phase 2 clinical trial in the U.S. and Europe. The company raised $12.8 million in a Series A to fund completion of that Phase 2 trial. The financing was led by Remiges Ventures and Lumira Ventures, and as part of the round Taka Koda of Remiges and Gerry Brunk of Lumira joined Cyrano's board. Cyrano intends to include patients with COVID-19-related smell loss as well as those whose dysfunction stems from other viral infections or causes such as influenza, allergic rhinitis and traumatic brain injury. The company was co-founded by CEO Rick Geoffrion and Robert Henkin, PhD, director of The Taste and Smell Clinic in Washington, D.C., after Geoffrion experienced long-term smell loss himself.